Guo Xiaomao

郭小毛

Professor, Chief Physician, Doctoral Supervisor, Party Secretary and President of Fudan University Shanghai Cancer Center, and President of Shanghai Proton and Heavy Ion Center

Radiation therapy including proton and heavy-ion therapy for breast, abdominal, and prostate malignancies, with multidisciplinary cancer care(乳腺肿瘤、腹部肿瘤和前列腺癌等的放射治疗，涵盖质子重离子治疗与多学科综合治疗)

Pioneering Contributions

Official SPHIC and FUSCC profiles position Guo Xiaomao as the current physician-leader of Shanghai's proton and heavy-ion program, serving as both the hospital president and Clinical Technology Committee Director.

Leadership & Positions

Party Secretary and President, Fudan University Shanghai Cancer Center
President, Shanghai Proton and Heavy Ion Center
Director, Clinical Technology Committee, Shanghai Proton and Heavy Ion Center
Vice President, Chinese Anti-Cancer Association
Chair, Radiation Oncology Committee, Chinese Anti-Cancer Association

Graduate

Shanghai Medical University

Request Consultation with Xiaomao

Notable Publications

Carbon Ion Radiotherapy Induce Metabolic Inhibition After Functional Imaging-Guided Simultaneous Integrated Boost for Prostate Cancer.

Frontiers in Oncology (2022) — co-author

PubMed/DOI

Immunomodulatory effects of carbon ion radiotherapy in patients with localized prostate cancer.

Journal of Cancer Research and Clinical Oncology (2023) — co-author

PubMed/DOI

Functional imaging-guided carbon ion irradiation with simultaneous integrated boost for localized prostate cancer: study protocol for a phase II randomized controlled clinical trial.

Trials (2022) — co-author

PubMed/DOI

Pioneering Contributions

Official SPHIC and FUSCC profiles position Guo Xiaomao as the current physician-leader of Shanghai's proton and heavy-ion program, serving as both the hospital president and Clinical Technology Committee Director.
His recent publication record includes carbon-ion radiotherapy studies in localized prostate cancer, spanning metabolic imaging, immunologic effects, and protocol development for phase II clinical evaluation.
His official profiles consistently frame his practice as integrating proton and heavy-ion radiotherapy into multidisciplinary care for breast, abdominal, and prostate cancers.

Sources — Guo Xiaomao

https://www.sphic.org.cn/lcystd/index_9.aspx—Current SPHIC clinical team roster showing Guo Xiaomao as current Clinical Technology Committee Director and Jiang Guoliang as Honorary Director(accessed Apr 16, 2026)
https://www.sphic.org.cn/lcystd/info_9.aspx?itemid=51—Official SPHIC profile for Guo Xiaomao, titles, specialty focus, and outpatient time(accessed Apr 16, 2026)
https://www.sphic.org.cn/lcystd/info_9.aspx?itemid=49—Official SPHIC profile for Jiang Guoliang, confirming honorary rather than current leadership status(accessed Apr 16, 2026)
https://www.shca.org.cn/Home/doctor/intro/pid/81—Official FUSCC physician profile confirming Guo Xiaomao as Party Secretary and President of FUSCC and President of Shanghai Proton and Heavy Ion Center(accessed Apr 16, 2026)
https://health.baidu.com/doctordec/jianjie/oslnov33qog4t3175j90—Secondary-source verification of 1993 graduation year and consistent current titles(accessed Apr 16, 2026)
https://pubmed.ncbi.nlm.nih.gov/35936669/—Publication verification for carbon-ion radiotherapy in prostate cancer(accessed Apr 16, 2026)
https://pubmed.ncbi.nlm.nih.gov/36138265/—Publication verification for immunomodulatory effects of carbon-ion radiotherapy(accessed Apr 16, 2026)
https://pubmed.ncbi.nlm.nih.gov/36348363/—Publication verification for phase II carbon-ion radiotherapy trial protocol(accessed Apr 16, 2026)

Request a case review with Guo Xiaomao

Guo Xiaomao practices at Fudan University Shanghai Cancer Center in Shanghai.

Request Case Review